<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02972372</url>
  </required_header>
  <id_info>
    <org_study_id>CRTESC6111</org_study_id>
    <nct_id>NCT02972372</nct_id>
  </id_info>
  <brief_title>Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer</brief_title>
  <acronym>CELAEC</acronym>
  <official_title>A Randomized, Open-label, Multicenter Trial of the Chemoradiation Versus Standard Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Cancer in Chinese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Henan University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anyang Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>150th Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Henan University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare outcomes in Chinese patients with locally advanced&#xD;
      resectable esophageal squamous cell cancer who have received either surgery or definitive&#xD;
      chemoradiation (CRT) by the randomized, open-label, multicenter trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: More than half of global esophageal cancer cases came from China, but the report&#xD;
      about definitive chemoradiation (CRT) compared with esophagectomy in Chinese patients with&#xD;
      locally advanced resectable esophageal squamous cell cancer (ESCC) is limited.&#xD;
&#xD;
      Aim: to compare outcomes in Chinese patients with locally advanced resectable esophageal&#xD;
      squamous cell cancer who have received either surgery or definitive chemoradiation (CRT).&#xD;
&#xD;
      Methods: 176 ESCC patients with T1bN+M0, T2-4aN0-2M0 will be randomized to CRT group or&#xD;
      Surgery group.In the CRT group, patients will be given intensity modulation radiation therapy&#xD;
      (IMRT) with 50Gy/25 fractions , and current chemotherapy with 5-fluorouracil (5-FU) basic&#xD;
      regimens. In the surgery group, patients will received standard esophagectomy. 5 years&#xD;
      follow-up for both groups patients.&#xD;
&#xD;
      Primary endpoints: 2 year and 5 year Disease free survival, Overall survival Second&#xD;
      endpoints: treatment-related adverse events; the quality of life&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year disease-free survival rate</measure>
    <time_frame>2 year</time_frame>
    <description>The percent of 2 year disease-free survival after random allocation, percent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>2 year</time_frame>
    <description>The percent of treatment-related adverse events after 2 year random allocation, percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoF (quality of life)</measure>
    <time_frame>2 year</time_frame>
    <description>The quality of life evaluation after 2 year of random allocation by questionnaire, 1-10 score, 1 means poor and 10 means best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 year overall survival</measure>
    <time_frame>2 year</time_frame>
    <description>The percent of 2 year overall survival after random allocation, percent</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Esophagus Cancer</condition>
  <arm_group>
    <arm_group_label>CRT group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in IMRT mode (total of 50Gy given in 25 fractions) will be given over a period 5-6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CRT</intervention_name>
    <description>Drug: Capecitabine(Aibin) capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total&#xD;
Other Names:&#xD;
Aibin Drug: Oxaliplatin(Aiheng) Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.&#xD;
Other Names:&#xD;
Aiheng cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85. 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.&#xD;
Radiation: Radiotherapy concurrent radiotherapy：IMRT radiotherapy 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity</description>
    <arm_group_label>CRT group</arm_group_label>
    <other_name>concurrent chemoradiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy</description>
    <arm_group_label>Surgery group</arm_group_label>
    <other_name>esophagectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chinese&#xD;
&#xD;
          -  esophageal squamous cell cancer&#xD;
&#xD;
          -  mid or lower esophageal cancer&#xD;
&#xD;
          -  tumor is resectable disease&#xD;
&#xD;
          -  clinical stage: cT1bN+Mo, or cT2-4aN0-2M0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  who had distant metastasis to solid visceral organs or local invasion into trachea,&#xD;
             descending aorta, or recurrent laryngeal nerve.&#xD;
&#xD;
          -  who had a serious premorbid condition or a poor physical status that compromised a&#xD;
             thoracotomy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shegan Gao, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fuyou Zhou, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Anyang Tumor Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruinuo Jia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shegan Gao, MD, PhD</last_name>
    <phone>+86 18638859977</phone>
    <email>gsg112258@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruinuo Jia, MD</last_name>
    <phone>+86 18537950766</phone>
    <email>jiaruinuo@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anyang Tumor Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuyou Zhou, MD,PhD</last_name>
      <phone>+86 13939998799</phone>
      <email>jiaruinuo@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shegan Gao, MD, PhD</last_name>
      <phone>+86 18638859977</phone>
      <email>gsg112258@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ruinuo Jia, MD</last_name>
      <phone>+86 18537950766</phone>
      <email>jiaruinuo@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ruinuo Jia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xinshuai Wang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guoqiang Kong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Baoping Chang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiachun Sun, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaozhi Yuan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dan Zhou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruina Yang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Ren, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuoguo Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shiyuan Song, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weijiao Yin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Teoh AY, Chiu PW, Yeung WK, Liu SY, Wong SK, Ng EK. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol. 2013 Jan;24(1):165-71. doi: 10.1093/annonc/mds206. Epub 2012 Aug 10.</citation>
    <PMID>22887465</PMID>
  </reference>
  <reference>
    <citation>Teoh AY, Yan Chiu PW, Wong TC, Liu SY, Hung Wong SK, Ng EK. Functional performance and quality of life in patients with squamous esophageal carcinoma receiving surgery or chemoradiation: results from a randomized trial. Ann Surg. 2011 Jan;253(1):1-5. doi: 10.1097/SLA.0b013e3181fcd991.</citation>
    <PMID>21233603</PMID>
  </reference>
  <reference>
    <citation>Park JW, Kim JH, Choi EK, Lee SW, Yoon SM, Song SY, Lee YS, Kim SB, Park SI, Ahn SD. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):691-7. doi: 10.1016/j.ijrobp.2010.06.041. Epub 2010 Oct 1.</citation>
    <PMID>20888705</PMID>
  </reference>
  <reference>
    <citation>Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.</citation>
    <PMID>23335087</PMID>
  </reference>
  <reference>
    <citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.</citation>
    <PMID>25651787</PMID>
  </reference>
  <reference>
    <citation>Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Chemoradiation for esophageal cancer. Thorac Surg Clin. 2013 Nov;23(4):551-8. doi: 10.1016/j.thorsurg.2013.07.006.</citation>
    <PMID>24199704</PMID>
  </reference>
  <reference>
    <citation>Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, Francois E, Crehange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Federation Francophone de Cancerologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18. Erratum In: Lancet Oncol. 2014 Dec;15(13):e587. Lancet Oncol. 2014 Dec;15(13):e587.</citation>
    <PMID>24556041</PMID>
  </reference>
  <reference>
    <citation>Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y, Fukuda H; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG). Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):684-90. doi: 10.1016/j.ijrobp.2010.06.033. Epub 2010 Oct 6.</citation>
    <PMID>20932658</PMID>
  </reference>
  <reference>
    <citation>Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, Tanaka M, Hironaka S, Hashimoto T, Ura T, Kodaira T, Yoshimura K. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol. 2013 Jun;43(6):608-15. doi: 10.1093/jjco/hyt048. Epub 2013 Apr 12.</citation>
    <PMID>23585687</PMID>
  </reference>
  <reference>
    <citation>Lee SJ, Ahn BM, Kim JG, Sohn SK, Chae YS, Moon JH, Lee EB, Kim JC, Park IK, Jeon SW. Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study. J Korean Med Sci. 2009 Feb;24(1):120-5. doi: 10.3346/jkms.2009.24.1.120. Epub 2009 Feb 28.</citation>
    <PMID>19270824</PMID>
  </reference>
  <reference>
    <citation>Xing L, Liang Y, Zhang J, Wu P, Xu D, Liu F, Yu X, Jiang Z, Song X, Zang Q, Wang W. Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer. J Cancer Res Clin Oncol. 2014 May;140(5):867-72. doi: 10.1007/s00432-014-1615-5. Epub 2014 Mar 1.</citation>
    <PMID>24578238</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 6, 2016</study_first_submitted>
  <study_first_submitted_qc>November 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2016</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophageal cancer</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>esophagectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02972372
org study id: CRTESC6111
nct id: NCT02972372
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
has dmc: Yes
The aim of this study is to compare outcomes in Chinese patients with locally advanced
      resectable esophageal squamous cell cancer who have received either surgery or definitive
      chemoradiation (CRT) by the randomized, open-label, multicenter trial.
Background: More than half of global esophageal cancer cases came from China, but the report
      about definitive chemoradiation (CRT) compared with esophagectomy in Chinese patients with
      locally advanced resectable esophageal squamous cell cancer (ESCC) is limited.

      Aim: to compare outcomes in Chinese patients with locally advanced resectable esophageal
      squamous cell cancer who have received either surgery or definitive chemoradiation (CRT).

      Methods: 176 ESCC patients with T1bN+M0, T2-4aN0-2M0 will be randomized to CRT group or
      Surgery group.In the CRT group, patients will be given intensity modulation radiation therapy
      (IMRT) with 50Gy/25 fractions , and current chemotherapy with 5-fluorouracil (5-FU) basic
      regimens. In the surgery group, patients will received standard esophagectomy. 5 years
      follow-up for both groups patients.

      Primary endpoints: 2 year and 5 year Disease free survival, Overall survival Second
      endpoints: treatment-related adverse events; the quality of life
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: 2-year disease-free survival rate
time frame: 2 year
description: The percent of 2 year disease-free survival after random allocation, percent
measure: Treatment-related adverse events
time frame: 2 year
description: The percent of treatment-related adverse events after 2 year random allocation, percent
measure: QoF (quality of life)
time frame: 2 year
description: The quality of life evaluation after 2 year of random allocation by questionnaire, 1-10 score, 1 means poor and 10 means best
measure: 2 year overall survival
time frame: 2 year
description: The percent of 2 year overall survival after random allocation, percent
arm group label: CRT group
arm group type: Active Comparator
description: 3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in IMRT mode (total of 50Gy given in 25 fractions) will be given over a period 5-6 weeks.
arm group label: Surgery group
arm group type: Active Comparator
description: The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
intervention type: Procedure
intervention name: CRT
description: Drug: Capecitabine(Aibin) capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total
Other Names:
Aibin Drug: Oxaliplatin(Aiheng) Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.
Other Names:
Aiheng cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85. 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.
Radiation: Radiotherapy concurrent radiotherapy：IMRT radiotherapy 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
arm group label: CRT group
other name: concurrent chemoradiotherapy
intervention type: Procedure
intervention name: surgery
description: The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
arm group label: Surgery group
other name: esophagectomy
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: No
last name: Shegan Gao, MD, PhD
role: Study Chair
affiliation: The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
last name: Fuyou Zhou, MD, PhD
role: Study Chair
affiliation: Anyang Tumor Hospital
last name: Ruinuo Jia, MD
role: Principal Investigator
affiliation: The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
last name: Shegan Gao, MD, PhD
phone: +86 18638859977
email: gsg112258@163.com
last name: Ruinuo Jia, MD
phone: +86 18537950766
email: jiaruinuo@163.com
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
investigator: 
investigator: 
investigator: 
investigator: 
investigator: 
investigator: 
investigator: 
investigator: 
investigator: 
investigator: 
investigator: 
investigator: 
country: China
citation: Teoh AY, Chiu PW, Yeung WK, Liu SY, Wong SK, Ng EK. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol. 2013 Jan;24(1):165-71. doi: 10.1093/annonc/mds206. Epub 2012 Aug 10.
PMID: 22887465
citation: Teoh AY, Yan Chiu PW, Wong TC, Liu SY, Hung Wong SK, Ng EK. Functional performance and quality of life in patients with squamous esophageal carcinoma receiving surgery or chemoradiation: results from a randomized trial. Ann Surg. 2011 Jan;253(1):1-5. doi: 10.1097/SLA.0b013e3181fcd991.
PMID: 21233603
citation: Park JW, Kim JH, Choi EK, Lee SW, Yoon SM, Song SY, Lee YS, Kim SB, Park SI, Ahn SD. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):691-7. doi: 10.1016/j.ijrobp.2010.06.041. Epub 2010 Oct 1.
PMID: 20888705
citation: Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
PMID: 23335087
citation: Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
PMID: 25651787
citation: Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Chemoradiation for esophageal cancer. Thorac Surg Clin. 2013 Nov;23(4):551-8. doi: 10.1016/j.thorsurg.2013.07.006.
PMID: 24199704
citation: Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, Francois E, Crehange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Federation Francophone de Cancerologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18. Erratum In: Lancet Oncol. 2014 Dec;15(13):e587. Lancet Oncol. 2014 Dec;15(13):e587.
PMID: 24556041
citation: Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y, Fukuda H; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG). Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):684-90. doi: 10.1016/j.ijrobp.2010.06.033. Epub 2010 Oct 6.
PMID: 20932658
citation: Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, Tanaka M, Hironaka S, Hashimoto T, Ura T, Kodaira T, Yoshimura K. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol. 2013 Jun;43(6):608-15. doi: 10.1093/jjco/hyt048. Epub 2013 Apr 12.
PMID: 23585687
citation: Lee SJ, Ahn BM, Kim JG, Sohn SK, Chae YS, Moon JH, Lee EB, Kim JC, Park IK, Jeon SW. Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study. J Korean Med Sci. 2009 Feb;24(1):120-5. doi: 10.3346/jkms.2009.24.1.120. Epub 2009 Feb 28.
PMID: 19270824
citation: Xing L, Liang Y, Zhang J, Wu P, Xu D, Liu F, Yu X, Jiang Z, Song X, Zang Q, Wang W. Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer. J Cancer Res Clin Oncol. 2014 May;140(5):867-72. doi: 10.1007/s00432-014-1615-5. Epub 2014 Mar 1.
PMID: 24578238
responsible party type: Sponsor
mesh term: Esophageal Neoplasms
sharing ipd: No